Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.46 |
| ▸ | ITGAV | P06756 | 16/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839645 | 0.93 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2842133 | 0.82 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2834629 | 0.81 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL4053910 | 0.81 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2839643 | 0.80 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2838647 | 0.80 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2836558 | 0.79 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL5856850 | 0.78 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2839453 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2838017 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.